Streetbeat News

Products Services

PDYPF

FanDuel Group President, Christian Genetski, praised the culture of Flutter and FanDuel, stating that sustaining market leadership will be based on the company's product during the Benzinga Sports Betting Titans Summit.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:17 pm

MGM

BetMGM CEO Adam Greenblatt expressed optimism about the growth potential of the iGaming and sports betting market during the Benzinga Titans Sports Betting Summit.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:11 pm

ELOX

Eloxx Pharmaceuticals plans to advance ELX-02 into a pivotal trial for treating Alport syndrome after achieving remission in one patient in its Phase 2 study. The patient demonstrated a significant reduction in urine protein creatinine ratio (UPCR). Eloxx has dosed three patients in the ongoing proof-of-concept Phase 2 open-label clinical trial.

Portfolio Pulse from Vandana Singh

May 24, 2023 | 4:02 pm

DKNG

DraftKings CEO Jason Robins announced that the company's horse racing app ranked #1 in the sports category on Kentucky Derby Day.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 3:46 pm

DKNG

DraftKings CEO Jason Robins stated at the Benzinga Titans Sports Betting Summit that the company has the widest variety of market and believes they need to offer everything people want to bet on.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 3:44 pm

ANF

Abercrombie & Fitch CEO Fran Horowitz appeared on CNBC to discuss the company's performance and future plans.

Portfolio Pulse from Happy Mohamed

May 24, 2023 | 3:41 pm

WVE

Wave Life Sciences' stock is trading lower after announcing that WVE-004 showed no clinical benefit compared to the placebo. Mizuho has reduced its price target on the stock from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 3:25 pm

PALI

Palisade Bio has been granted European Patent Number EP3209306, titled 'Stable Neural Stem Cells Comprising An Exogenous Polynucleotide Coding For A Growth Factor And Methods Of Use Thereof'.

Portfolio Pulse from Happy Mohamed

May 24, 2023 | 3:19 pm

AZTR

Azitra Inc (NASDAQ:AZTR) is set to IPO on May 25, offering shares at an expected price between $4.50 and $5.50 per share. The company focuses on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 3:03 pm

TRYPF

Tryp Therapeutics has submitted an Investigational New Drug application to the FDA for a phase 2a clinical trial of psilocybin-assisted psychotherapy in treating patients with irritable bowel syndrome (IBS) at Massachusetts General Hospital. The study will be conducted in collaboration with Harvard Medical School/Massachusetts General Hospital.

Portfolio Pulse from Vuk Zdinjak

May 24, 2023 | 3:01 pm